ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pastor, A
Right arrow Articles by Aznar, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pastor, A
Right arrow Articles by Aznar, J
Eur Respir J 1997; 10: 603-609
Copyright © ERS Journals Ltd 1997

Original Articles

Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis

A Pastor, R Menendez, MJ Cremades, V Pastor, R Llopis, and J Aznar

The aim of this study was to evaluate the diagnostic value of three tumour markers, squamous cell carcinoma (SCC) antigen, carcinoembryonic antigen (CEA) and CYFRA 21.1, in lung cancer using a Bayesian analysis to obtain the predictive values for different pretest probabilities or prevalences. A cross-sectional study included 94 patients with lung cancer, 40 with benign lung disease, and 40 healthy controls. SCC antigen and CEA were measured in blood samples by microparticle enzyme immunoassay (MEIA), and CYFRA by enzyme-linked immunosorbent assay (ELISA). The results of tumour marker determinations were expressed as percentiles, and showed significantly higher levels in the cancer group than in the two control groups. Taking the 95th percentile of benign lung diseases as the cut-off point (specificity 95%), the following sensitivities were found: SCC 41%, CEA 31% and CYFRA 79%. After a Bayesian analysis, the best results for the three tumour markers were found in prevalences of 30-40%. The highest incremental gain was obtained by CYFRA (at prevalence of 36%, positive and negative predictive value approximately 90%). The three tumour markers were included in a stepwise regression analysis to predict lung cancer, and CYFRA was the only selected variable. We conclude that CYFRA 21.1 may be a useful marker in lung cancer when there is an intermediate pretest probability of disease.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
S. Ocak, M. L. Sos, R. K. Thomas, and P. P. Massion
High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications
Eur. Respir. J., August 1, 2009; 34(2): 489 - 506.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
S. Ocak, P. Chaurand, and P. P. Massion
Mass Spectrometry-based Proteomic Profiling of Lung Cancer
Proceedings of the ATS, April 15, 2009; 6(2): 159 - 170.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. D. Petty, K. M. Kerr, G. I. Murray, M. C. Nicolson, P. H. Rooney, D. Bissett, and E. S.R. Collie-Duguid
Tumor Transcriptome Reveals the Predictive and Prognostic Impact of Lysosomal Protease Inhibitors in Non-Small-Cell Lung Cancer
J. Clin. Oncol., April 10, 2006; 24(11): 1729 - 1744.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. H. Lee and J. H. Chang
Diagnostic Utility of Serum and Pleural Fluid Carcinoembryonic Antigen, Neuron-Specific Enolase, and Cytokeratin 19 Fragments in Patients With Effusions From Primary Lung Cancer
Chest, October 1, 2005; 128(4): 2298 - 2303.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S.-i. Fukumoto, N. Yamauchi, H. Moriguchi, Y. Hippo, A. Watanabe, J. Shibahara, H. Taniguchi, S. Ishikawa, H. Ito, S. Yamamoto, et al.
Overexpression of the Aldo-Keto Reductase Family Protein AKR1B10 Is Highly Correlated with Smokers' Non-Small Cell Lung Carcinomas
Clin. Cancer Res., March 1, 2005; 11(5): 1776 - 1785.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
C. Prados, R. Alvarez-Sala, J. G. d. Terreros, L. Callol, F. G. Rio, L. G. Carrera, J. G. d. T. Caro, J. L. Alvarez-Sala, D. Espinos, and J. Villamor
An Evaluation of Tissue Polypeptide Antigen (TPA) in the Two Bronchoalveolar Lavage Fractions of Lung Cancer Patients
Jpn. J. Clin. Oncol., May 1, 2000; 30(5): 215 - 220.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the European Respiratory Society.